在黑色素瘤中,CoREST抑制器综合体调解了表型切换和治疗耐药性
Muzhou Wu1, Ailish Hanly1, Frederick Gibson1
1Department of Dermatology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
The Journal of clinical investigation
|February 1, 2024
概括
向COREST表观遗传抑制器复合体,可重编程黑色素瘤细胞表型,克服对BRAF抑制剂 (BRAFi) 的耐药性. 这种方法通过逆转DUSP1下调和抑制p38 MAPK活性,使BRAFi耐药黑色素瘤重新敏感于治疗.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 通过非突变机制,BRAF突变黑色素瘤经常对MAPK抑制剂产生耐药性.
- 表观遗传变化与癌症治疗耐药性有关,但具体的目标仍然难以捉摸.
- 黑色素瘤表现出类型可塑性,有助于治疗挑战.
研究的目的:
- 研究CoREST表观遗传抑制器复合体在黑色素瘤表型可塑性和治疗耐药性中的作用.
- 为了评估双价CoREST抑制剂 - - 科林在克服BRAF抑制剂耐药性的有效性.
- 为了确定Corin对黑色素瘤细胞影响的分子机制.
主要方法:
- 评估了COREST复合体对黑色素瘤表型的参与.
- 用科林治疗黑色素瘤细胞并分析全球的转录和染色质变化.
- 研究了对基因组标记,EMT相关的转录因子和DUSP的影响.
- 评估了科林能够使BRAFi抑制剂耐药 (BRAFi-R) 黑色素瘤模型对BRAFi治疗重新敏感的能力.
- 使用p38 MAPK抑制剂BIRB 796进行比较分析.
主要成果:
- CoREST被确定为黑色素瘤表型的关键调解者.
- 科林治疗诱导了黑色素瘤细胞表型重编程和改变了特定的组织蛋白标记.
- 科林在BRAFi-R黑色素瘤中逆转了DUSP1下调,抑制了p38 MAPK活性.
- 科林治疗使BRAFi-R黑色素瘤对BRAFi治疗重新敏感.
- 通过p38 MAPK抑制,可林所观察到的效应部分得到了回顾.
结论:
- CoREST抑制器复合体是黑色素瘤表型可塑性和对向疗法的耐药性的中央调节器.
- 作为一个CoREST抑制剂的Corin在重编程黑色素瘤表型和克服BRAFi耐药性方面表现出潜力.
- CoREST 抑制剂是 BRAFi 耐药黑色素瘤患者的一种有前途的治疗策略.
相关概念视频
Co-activators and Co-repressors
7.4K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.4K
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K


